Odonate

ODTC · OTC

$50,000.00−$126,040.00 (−71.60%)TodayMarket closed · Feb 4, 11:27 AM ET

No price history for this range.

About ODTC

Odonate, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improve and extend the lives of patients with cancer. The firm is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The firm is no longer in development of tesetax.

Employees: 137
Headquarters: San Diego, Texas
Listed: Dec 7, 2017
Sector: Health Care
Industry: Pharmaceuticals
Website: odonate.com

Leadership

Odonate executives
Name	Title	Since	Age
Kevin Tang	—	2013	—
Michael Hearne	—	—	58
Robert Rosen	—	—	66
Aaron Davis	—	—	—
Laura Douglass	—	—	57
Craig Johnson	—	—	61

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Odonate suppliers and customers
Company	Relationship	Country	Correlation
Daiichi Sankyo	Supplier and customer	JP	—

Similar companies

Companies in the same industry as Odonate

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.